Khaled Mohamed Abdelwahab

Dr. Khaled Mohamed Abdelwahab


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2023 in Cancers
Verified
Journal Article
Open access
PDF file
BEBasma Mamdouh Elsayed
Basma Mamdouh Elsayed
AAAhmed AlKsas
Ahmed AlKsas
Mohamed ShehataMohamed Shehata
Mohamed Shehata
MHMahmoud Ali H.
Mahmoud Ali H.
MZMona Zaky
Mona Zaky
Ayman El-BazAyman El-Baz
Ayman El-Baz
Breast cancer retains its position as the most prevalent form of malignancy among females on a global scale. The careful selection of appropriate treatment for each patient holds paramount importance in effectively managing breast cancer. Neoadjuvant chemotherapy (NACT) plays a pivotal role in the comprehensive treatment of this disease. Administering chemotherapy before surgery, NACT becomes a powerful tool in reducing tumor size, potentially enabling fewer invasive surgical procedures and even rendering initially inoperable tumors amenable to surgery. However, a significant challenge lies in the varying responses exhibited by different patients towards NACT. To address this challenge, researchers have focused on developing prediction models that can identify those who would benefit from NACT and those who would not. Such models have the potential to reduce treatment costs and contribute to a more efficient and accurate management of breast cancer. Therefore, this review has two objectives: first, to identify the most effective radiomic markers correlated with NACT response, and second, to explore whether integrating radiomic markers extracted from radiological images with pathological markers can enhance the predictive accuracy of NACT response. This review will delve into addressing these research questions and also shed light on the emerging research direction of leveraging artificial intelligence techniques for predicting NACT response, thereby shaping the future landscape of breast cancer treatment.

9 January 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
AIAfaf T. Ibrahiem
Afaf T. Ibrahiem
EEEntsar Eladl
Entsar Eladl
ETEman Toraih
Eman Toraih
Manal S. FawzyManal S. Fawzy
Manal S. Fawzy
KAKhaled Mohamed Abdelwahab
Khaled Mohamed Abdelwahab
NSNahed Ahmed Soliman
Nahed Ahmed Soliman
Patients with colorectal cancer in different stages show variable outcomes/therapeutic responses due to their distinct tumoral biomarkers and biological features. In this sense, this study aimed to explore the prognostic utility of BRAF, programmed death-1 (PD1), and its ligand (PDL1) protein signatures in colon adenocarcinoma. The selected protein markers were explored in 64 archived primary colon adenocarcinomas in relation to clinicopathological features. BRAF overexpression was found in 39% of the cases and was significantly associated with grade 3, N1, advanced Dukes stage, presence of relapse, and shorter overall survival (OS). PD1 expression in the infiltrating immune cells (IICs) exhibited significant association with T2/T3, N0/M0, early Dukes stage, and absence of relapse. PDL1 expression in IICs is significantly associated with advanced nodal stage/distant metastasis, advanced Dukes stage, and shorter OS. Meanwhile, PDL1 expression in neoplastic cells (NC) was associated with the advanced lymph node/Dukes stage. A positive combined expression pattern of PDL1 in NC/IICs was associated with poor prognostic indices. Tumor PDL1 expression can be an independent predictor of OS and DFS. The multivariate analyses revealed that short OS was independently associated with the RT side location of the tumor, PD1 expression in stromal IICs, and PDL1 expression in NC. In conclusion, overexpression of BRAF in colon adenocarcinoma is considered a poor prognostic pathological marker. In addition, PDL1 expression in NC is considered an independent prognostic factor for DFS/OS. Combined immunohistochemical assessment for BRAF and PD1/PDL1 protein expressions in colon adenocarcinoma might be beneficial for selecting patients for future targeted therapy.

1 January 2025 in Surgery, Gastroenterology and Oncology
Verified
Journal Article
Open access
PDF file
KAKhaled Mohamed Abdelwahab
Khaled Mohamed Abdelwahab
SESara Elsaeed
Sara Elsaeed
SSSaleh Saleh
Saleh Saleh
OHOmar Hamdy
Omar Hamdy
RARadwa M. Abdelsattar
Radwa M. Abdelsattar
MSMosab Shetiwy
Mosab Shetiwy
Background: Phyllodes tumors (PT) of the breast represent a rare entity of breast neoplasms, their unpredictable behavior and high recurrence potential present these tumors as a clinical challenge. Those tumors necessitate careful diagnostic evaluation and management. Our retrospective study aims to discuss the different clinico-pathological features as well as different management approaches for phyllodes tumors. Methods: A retrospective review of 175 PT patients diagnosed and treated in our institution between 2006 and 2023 was conducted. Data were collected from the medical records of our oncology center. The patients' epidemiological, clinical, pathological, therapeutic, and oncological data were analyzed. Results: Our results denoted the mean age of PTs diagnosis to be 42.2 (14-81) years, with a mean radiological size of 57.76 (8-200) mm. The incidence of malignant PTs was 17.8% (31 cases). All patients in our research received surgery as their primary treatment, where 51 (29.5%) underwent lumpectomy and 91 (52.6%) underwent wide local excision. Mastectomy was the treatment used for 27 (15.6%) patients. 16.4% of PT patients (28/170) experienced recurrence, with a mean follow-up period of 161.93 months. Malignant recurrence was reported mainly among patients > 35 years old (13/16 patients, p value= 0.56). The mean DFS of malignant phyllodes in this cohort was 67.27 months (95% CI: 32.9-101.6 months). The mean OAS of malignant phyllodes in this cohort was 112.82 months (95% CI: 68.2-157.4 months), while non-malignant pathology had a OAS mean of 177.54 months (95% CI: 158.1-197 months). Conclusion: Phyllodes tumors of the breast pose significant clinical challenges. Worse prognosis was noted in older age groups, larger tumor size, and higher tumor grade. Achieving clear surgical margins, and maintaining rigorous long-term follow-up are the cornerstone management of PTs. Still future studies with larger sample sizes are needed.

19 August 2026 in Discover Oncology
Verified
Journal Article
Open access
PDF file
AFAhmed M. Fareed
Ahmed M. Fareed
FSFarida A. Shokeir
Farida A. Shokeir
EAEssam Attia
Essam Attia
OHOmar Hamdy
Omar Hamdy
SSSaleh Saleh
Saleh Saleh
KAKhaled Mohamed Abdelwahab
Khaled Mohamed Abdelwahab
Introduction Estrogen receptor (ER) negative/progesterone receptor (PR) positive is an infrequently reported biological subtype of breast cancer (BC). Various authors have treated its existence doubtfully. To our knowledge, this study is the first within Egypt and the Middle East to investigate this rare subgroup of BC. Methods This retrospective study included all ER−/PR + BC patients treated in our center from 2016 to 2022. The collected data were coded, processed, and analyzed using IBM SPSS. Results The study included 149 patients with ER−/PR + breast cancer. The mean age was 50.3 years (21–83). The mean follow-up interval was 68 months. pT1 represented 20.8% of the cases, pT2 tumors were 50%, pT3 tumors were 16.7%, while pT4 tumors were 5.6%. As regards nodal staging, pN0 were 36.3%, pN1 24.7%, pN2 19.2%, and pN3 19.8%. The main histology of the tumors was infiltrating duct carcinoma (81.2%), followed by lobular carcinoma (8.7%). Weak PR positivity (Allred score < 6) was documented in 92 patients (61.7%). While the remaining patients showed strong PR positivity (scores of 6 or higher), 68% were HER2 receptor-negative. In the follow-up period, 39% of the patients suffered from disease relapse. The mean disease-free survival was 60.8 months, and the mean overall survival was 69.8 months. The nodal status was the only variable that significantly affected disease-free and overall survival in the univariate analysis, while no factor affected survival in the multivariate analysis. Conclusion ER−/PR + breast cancer seems to be an underestimated subtype, which is more aggressive than double-positive hormonal receptor breast cancer but less aggressive than double-negative hormonal receptor breast cancer.